Article

Rituximab Hit With FDA Warning on HBV Risk

A black box warning has been added to the label of the commonly used anti-inflammatory drug rituximab warning that it may reactivate hepatitis B virus.

The US Food and Drug Administration has added a black box warning that ofatumumab (Arzerra) and rituximab (Rituxan) may reactivate hepatitis B virus (HBV).

Rituximab is used to treat rheumatoid arthritis and granulomatosis with polyangiitis, and both drugs are used for leukemia and lymphoma.

Patients should be screened for HBV with hepatitis B surface antigen and hepatitis B core antibody, says the notice.

If the result is positive:

1. Consult a hepatitis expert.

2. Monitor patients using these drugs for HBV.

3. If reactivated, stop and treat for HBV

Related Videos
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
Considering Viral Infections in Patients With Rheumatic Disease With Leonard Calabrese, DO
Leonard H. Calabrese, DO, Professor of Medicine and Vice Chair, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Alvin Wells, MD, PhD: Making Informed Treatment Decisions With New Testing Strategies
Alvin Wells, MD, PhD
Upcoming Research in PsA, AxSpa, with Philip Mease, MD
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine and Director, Rheumatology Research, Swedish Medical Center
Related Content
Claire Immediato Daien, professor, rheumatology, Centre Hospitalier Universitaire de Montpellier, France
October 23rd 2024

Multimorbidity Screening Reduced Hospitalizations in Patients With Rheumatic Diseases

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Laura YL Kummer, Doctorate Student / Research Assistant. Department of Immunopathology, Sanquin Research
October 22nd 2024

Methotrexate May Lower Vaccine Response in Patients With RA

Victoria Johnson
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
James Helliwell, MD, cofounder and CEO, Eupraxia
October 18th 2024

EP-104IAR Phase 2 Data Shows Potential for Knee Osteoarthritis Pain

Victoria Johnson
Lauma Ievina, PhD candidate, The Institute of Microbiology and Virology of the Riga Stradiņš University Science Hub, Latvia
October 18th 2024

Study Identifies Gut Microbiome Makeup, Diversity Differences in People With Fibromyalgia

Victoria Johnson
© 2024 MJH Life Sciences

All rights reserved.